Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 6Breast Neoplasms 4Recurrence 2Oligodendroglioma 2Meningeal Carcinomatosis 2Glioblastoma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Meningeal Neoplasms 1Melanoma 1Lung Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × paclitaxel-Angiopep-2 conjugate × Clear all
NCT01967810 2020-02-25

ANG1005 in Patients With Recurrent High-Grade Glioma

Angiochem Inc

Phase 2 Completed
73 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Recurrence

NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Angiochem Inc

Phase 1 Completed
63 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡